This article is more than 5 years old. Information may no longer be current.

Servier’s oncology presence includes treatments for gastrointestinal cancers, hematologic malignancies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Yann Orsi, head of global therapeutic area oncology at Servier Group, spoke with HemOnc Today about its philosophy and research efforts.

Servier — which participated in ASCO Annual Meeting for the first time since establishing a presence in the United States last year — comprises an international group that operates in 149 countries.

The company — operated by a nonprofit foundation — is commercializing five different treatments in oncology. These include therapies for metastatic colorectal cancer, pancreatic cancer, acute lymphoblastic leukemia and non-Hodgkin lymphoma.